Literature DB >> 22949395

Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation.

Marie Marduel1, Khadija Ouguerram, Valérie Serre, Dominique Bonnefont-Rousselot, Alice Marques-Pinheiro, Knut Erik Berge, Martine Devillers, Gérald Luc, Jean-Michel Lecerf, Laurent Tosolini, Danièle Erlich, Gina M Peloso, Nathan Stitziel, Patrick Nitchké, Jean-Philippe Jaïs, Marianne Abifadel, Sekar Kathiresan, Trond Paul Leren, Jean-Pierre Rabès, Catherine Boileau, Mathilde Varret.   

Abstract

Apolipoprotein (apo) E mutants are associated with type III hyperlipoproteinemia characterized by high cholesterol and triglycerides levels. Autosomal dominant hypercholesterolemia (ADH), due to the mutations in the LDLR, APOB, or PCSK9 genes, is characterized by an isolated elevation of cholesterol due to the high levels of low-density lipoproteins (LDLs). We now report an exceptionally large family including 14 members with ADH. Through genome-wide mapping, analysis of regional/functional candidate genes, and whole exome sequencing, we identified a mutation in the APOE gene, c.500_502delTCC/p.Leu167del, previously reported associated with sea-blue histiocytosis and familial combined hyperlipidemia. We confirmed the involvement of the APOE p.Leu167del in ADH, with (1) a predicted destabilization of an alpha-helix in the binding domain, (2) a decreased apo E level in LDLs, and (3) a decreased catabolism of LDLs. Our results show that mutations in the APOE gene can be associated with bona fide ADH.
© 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22949395      PMCID: PMC3638718          DOI: 10.1002/humu.22215

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  29 in total

1.  Familial splenomegaly: macrophage hypercatabolism of lipoproteins associated with apolipoprotein E mutation [apolipoprotein E (delta149 Leu)].

Authors:  T T Nguyen; K E Kruckeberg; J F O'Brien; Z S Ji; P S Karnes; T B Crotty; I D Hay; R W Mahley; T O'Brien
Journal:  J Clin Endocrinol Metab       Date:  2000-11       Impact factor: 5.958

2.  A presumptive new locus for autosomal dominant hypercholesterolemia mapping to 8q24.22.

Authors:  A Cenarro; A-L García-Otín; M T Tejedor; M Solanas; E Jarauta; C Junquera; E Ros; P Mozas; J Puzo; M Pocoví; F Civeira
Journal:  Clin Genet       Date:  2011-05       Impact factor: 4.438

3.  Sea-blue histiocytosis associated with hyperlipidaemia.

Authors:  A C Parker; A D Bain; W G Brydon; R A Harkness; A F Smith; I I Smith; D H Boyd
Journal:  J Clin Pathol       Date:  1976-07       Impact factor: 3.411

4.  The spleen in type I hyperlipoproteinemia. Histochemical, biochemical, microfluorometric and electron microscopic observations.

Authors:  V J Ferrans; L M Buja; W C Roberts; D S Fredrickson
Journal:  Am J Pathol       Date:  1971-07       Impact factor: 4.307

5.  Sea-blue histiocytosis in hyperlipoproteinemia (cytomorphological, clinical and pathogenetic aspects).

Authors:  G Castoldi; G D Grusovin; G Scapoli
Journal:  Haematologica       Date:  1974-03       Impact factor: 9.941

6.  Ceroid histiocytosis of the spleen in hyperlipemia: relationship to the syndrome of the sea-blue histiocyte.

Authors:  A M Rywlin; A Lopez-Gomez; P Tachmes; V Pardo
Journal:  Am J Clin Pathol       Date:  1971-11       Impact factor: 2.493

7.  Sea blue histiocytosis associated with hyperlipoproteinemia type IIb.

Authors:  Y B Lee; H Kim; C I Park; C S Kim; I J Choi; K Y Kim; Y H Moon
Journal:  Yonsei Med J       Date:  1983       Impact factor: 2.759

8.  Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site.

Authors:  K H Weisgraber; T L Innerarity; R W Mahley
Journal:  J Biol Chem       Date:  1982-03-10       Impact factor: 5.157

Review 9.  Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia). Questions, quandaries, and paradoxes.

Authors:  R W Mahley; Y Huang; S C Rall
Journal:  J Lipid Res       Date:  1999-11       Impact factor: 5.922

10.  Cholesterol ester storage disease in an adult presenting with sea-blue histiocytosis.

Authors:  G T Besley; D M Broadhead; E Lawlor; S R McCann; J D Dempsey; M I Drury; J Crowe
Journal:  Clin Genet       Date:  1984-09       Impact factor: 4.438

View more
  37 in total

1.  Exome sequencing in suspected monogenic dyslipidemias.

Authors:  Nathan O Stitziel; Gina M Peloso; Marianne Abifadel; Angelo B Cefalu; Sigrid Fouchier; M Mahdi Motazacker; Hayato Tada; Daniel B Larach; Zuhier Awan; Jorge F Haller; Clive R Pullinger; Mathilde Varret; Jean-Pierre Rabès; Davide Noto; Patrizia Tarugi; Masa-Aki Kawashiri; Atsushi Nohara; Masakazu Yamagishi; Marjorie Risman; Rahul Deo; Isabelle Ruel; Jay Shendure; Deborah A Nickerson; James G Wilson; Stephen S Rich; Namrata Gupta; Deborah N Farlow; Benjamin M Neale; Mark J Daly; John P Kane; Mason W Freeman; Jacques Genest; Daniel J Rader; Hiroshi Mabuchi; John J P Kastelein; G Kees Hovingh; Maurizio R Averna; Stacey Gabriel; Catherine Boileau; Sekar Kathiresan
Journal:  Circ Cardiovasc Genet       Date:  2015-01-27

2.  PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE.

Authors:  Brandon Ason; José W A van der Hoorn; Joyce Chan; Edward Lee; Elsbet J Pieterman; Kathy Khanh Nguyen; Mei Di; Susan Shetterly; Jie Tang; Wen-Chen Yeh; Margrit Schwarz; J Wouter Jukema; Rob Scott; Scott M Wasserman; Hans M G Princen; Simon Jackson
Journal:  J Lipid Res       Date:  2014-09-25       Impact factor: 5.922

Review 3.  The Spectrum of Familial Hypercholesterolemia (FH) in Saudi Arabia: Prime Time for Patient FH Registry.

Authors:  Faisal Alallaf; Fatima Amanullah H Nazar; Majed Alnefaie; Adel Almaymuni; Omran Mohammed Rashidi; Khalid Alhabib; Fahad Alnouri; Mohamed-Nabil Alama; Mohammad Athar; Zuhier Awan
Journal:  Open Cardiovasc Med J       Date:  2017-07-26

4.  Genetic diagnosis of familial hypercholesterolemia is associated with a premature and high coronary heart disease risk.

Authors:  Florent Séguro; Jean-Pierre Rabès; Dorota Taraszkiewicz; Jean-Bernard Ruidavets; Vanina Bongard; Jean Ferrières
Journal:  Clin Cardiol       Date:  2018-03-25       Impact factor: 2.882

Review 5.  Exome sequencing greatly expedites the progressive research of Mendelian diseases.

Authors:  Xuejun Zhang
Journal:  Front Med       Date:  2014-01-03       Impact factor: 4.592

6.  Usefulness of the genetic risk score to identify phenocopies in families with familial hypercholesterolemia?

Authors:  Youmna Ghaleb; Sandy Elbitar; Petra El Khoury; Eric Bruckert; Valérie Carreau; Alain Carrié; Philippe Moulin; Mathilde Di-Filippo; Sybil Charriere; Harout Iliozer; Michel Farnier; Gérald Luc; Jean-Pierre Rabès; Catherine Boileau; Marianne Abifadel; Mathilde Varret
Journal:  Eur J Hum Genet       Date:  2018-01-26       Impact factor: 4.246

7.  The M2 module of the Cys-His-rich domain (CHRD) of PCSK9 protein is needed for the extracellular low-density lipoprotein receptor (LDLR) degradation pathway.

Authors:  Yascara Grisel Luna Saavedra; Robert Day; Nabil G Seidah
Journal:  J Biol Chem       Date:  2012-10-26       Impact factor: 5.157

Review 8.  My Approach to the Patient With Familial Hypercholesterolemia.

Authors:  Maya S Safarova; Iftikhar J Kullo
Journal:  Mayo Clin Proc       Date:  2016-06       Impact factor: 7.616

9.  Global molecular analysis and APOE mutations in a cohort of autosomal dominant hypercholesterolemia patients in France.

Authors:  René Wintjens; Dominique Bozon; Khaldia Belabbas; Félicien MBou; Jean-Philippe Girardet; Patrick Tounian; Mathilde Jolly; Franck Boccara; Ariel Cohen; Alexandra Karsenty; Béatrice Dubern; Jean-Claude Carel; Ahlam Azar-Kolakez; François Feillet; François Labarthe; Anne-Marie Colin Gorsky; Alice Horovitz; Catherine Tamarindi; Pierre Kieffer; Anne Lienhardt; Olivier Lascols; Mathilde Di Filippo; Fabienne Dufernez
Journal:  J Lipid Res       Date:  2016-01-22       Impact factor: 5.922

Review 10.  Exome sequencing: new insights into lipoprotein disorders.

Authors:  Sali M K Farhan; Robert A Hegele
Journal:  Curr Cardiol Rep       Date:  2014-07       Impact factor: 2.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.